louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03624751: Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment
Official title: Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Thyroid Cancer
Lead sponsor: Taichung Veterans General Hospital
Sponsor class: OTHER
First posted: 2018-08-10
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with diagnosis of thyroid cancer

Brief summary: The prevalence of thyroid cancer has increased in recent decades. Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan. This is a prospective, observational study, aiming to observe the difference of metabolic profiles between patients choose Thyrogen® injection and Eltroxin® withdrawal.

Detailed description: 1. Objective： To observe the difference between Thyogen® injection or Eltroxin® withdrawal on metabolic profile.
2. Background and method:： The prevalence of thyroid cancer has increased in recent decades. Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan. This is a prospective, observational study, aiming to observe the difference of metabolic profiles between patients choose Thyrogen® injection and Eltroxin® withdrawal.

Inclusion ： Patient number: 500人

Inclusion criteria :

1. Patients with diagnosis of thyroid cancer。
2. Patients who need radioiodine therapy or scan。

Exclusion criteria:

1. Patients cannot cooperate with blood test.。
2. Patients cannot cooperate with radioiodine therapy。 Study design： Prospective, observational study。

Method： We will collect 20cc blood and 20 cc urine before and after radioiodine therapy during each visit (total 3 visits) and check lipid profiles, glucose profiles and inflammation markers. We will compare the difference between results of patients undergoing Thyrogen® injection and Eltroxin® withdrawal.

Eligibility criteria: Inclusion Criteria:

1. Patients with diagnosis of thyroid cancer。
2. Patients who need radioiodine therapy or scan。

Exclusion Criteria:

1. Patients cannot cooperate with blood test.。
2. Patients cannot cooperate with radioiodine therapy。

Primary outcomes:
measure: Zung's Self-reported depression scale
timeFrame: 1 month
Secondary outcomes:
measure: Brain-derived neurotrophic factor
timeFrame: 1 month
measure: orexin
timeFrame: 1 month
measure: Body composition
timeFrame: 1 months
measure: VCAM-1
timeFrame: 1 months
measure: CRP
timeFrame: 1 months
measure: Metabolic syndrome
timeFrame: 1 months
Other outcomes:
Locations:
city: Taichung
country: Taiwan
facility: Division of Endocrinology and Metabolism in Taichung Veterans General Hospital
Study officials:
References:
Clinical trial NCT05127551: Clinical Study of Glaukos® Trabecular Micro-Bypass System Model iS3 Infinite Vs. Competitor
Official title: A Prospective, Randomized, Controlled, Comparitive Multicenter Clinical Study of Glaukos® Trabecular Micro-Bypass System Model iS3 Infinite® vs Competitor in Adult Subjects With Primary Open-Angle Glaucoma (POAG)
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Glaucoma
Glaucoma, Open-Angle
Keywords: Glaucoma
MIGS
Lead sponsor: Glaukos Corporation
Sponsor class: INDUSTRY
First posted: 2021-11-19
Enrollment: 179
Sex: ALL
Minimum age (years): 35
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A study of the iStent Infinite product in the treatment of open-angle glaucoma vs competitor


Eligibility criteria: Inclusion Criteria:

* Diagnosis of Primary Open-Angle Glaucoma (POAG) or Secondary Pseudoexfoliative Glacoma (PEXG) or Secondary Pigmentary Glaucoma (PG)

Exclusion Criteria:

* Any other type of glaucoma including, but not limited to: traumatic glaucoma, angle recession glaucoma, uveitic glaucoma, neovascular glaucoma, angle closure glaucoma (ACG) and glaucoma associated with vascular disorders

Primary outcomes:
measure: Change in Mean Diurnal Intraocular Pressure
timeFrame: Month 24
Secondary outcomes:
Other outcomes:
Locations:
city: Montréal
country: Canada
facility: Glaukos Investigator Sites
state: Qubec
Study officials:
References:
Clinical trial NCT03762551: Janus Kinase 1 in Vitiligo & Psoriasis
Official title: Expression of Janus Kinase 1 in Vitiligo and Psoriasis Before and After Narrow Band UVB: a Case-Control Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Vitiligo
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2018-12-03
Enrollment: 30
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Assessment of the level of JAK1 in both vitiligo and psoriasis patients before and after treatment with NB-UVB which is considered a gold standard therapy for both diseases.


Eligibility criteria: Inclusion Criteria:

* age above 12 years of age.
* psoriasis vulgaris or non-segmental vitiligo
* patients who received no systemic or topical treatment at least 6 weeks prior to enrollment into the study.

Exclusion Criteria:

* psoriasis patients with erythrodermic psoriasis, pustular psoriasis or associated psoriatic arthritis
* vitiligo patients with segmental or universal vitiligo were excluded from the study.
* any patient with a photosensitive disorder or any contraindication to phototherapy exposure, e.g., history or presence of malignant or premalignant skin lesions.

Primary outcomes:
measure: Measurement of the tissue level of JAK1 in both vitiligo and psoriasis patients before and after treatment with NB-UVB
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04867551: A Clinical Study of KDT-3594 in Japanese Patients With Early Parkinson's Disease
Official title: A Phase II Clinical Study of KDT-3594 in Japanese Patients With Early Parkinson's Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Parkinson Disease
Lead sponsor: Kissei Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2021-04-30
Enrollment: 7
Sex: ALL
Minimum age (years): 20
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Objective of this study is to investigate the safety, pharmacokinetics and efficacy of KDT-3594 in patients with early Parkinson's disease without a concomitant medication of L-dopa.


Eligibility criteria: Inclusion Criteria:

* Japanese patients
* Patients who are diagnosed with Parkinson's disease according to UK Parkinson's Disease society brain bank clinical diagnostic criteria
* Patients with Parkinson's disease in Stages 1 to 3 on the Modified Hoehn and Yahr Scale

Exclusion Criteria:

* Patients who are suspected any parkinsonism except for idiopathic Parkinson's disease.
* Patients who underwent neurosurgical treatment (stereotaxic destruction, deep brain stimulation etc.) for PD, or patients for whom surgical treatment is scheduled during the study
* Patients with a complication of obvious dementia, or patients with Mini-Mental State Examination (MMSE) score \< 24 points

Primary outcomes:
measure: Occurrence of adverse events
timeFrame: 8 weeks
measure: Plasma concentrations of KDT-3594 and its metabolites
timeFrame: 8 weeks
Secondary outcomes:
measure: Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Multiple Locations
country: Japan
facility: Research Site
Study officials:
affiliation: Kissei Pharmaceutical Co., Ltd.
name: Yoshitaka Shimizu
role: STUDY_DIRECTOR
References:
Clinical trial NCT04432051: The Use of Lung Ultrasonography in COVID-19 Patients
Official title: The Significance of Lung Ultrasonography in the Follow-up and Treatment of COVID-19 Patients With Respiratory Failure
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Ultrasonography
Keywords: lung ultrasonography
intensive care unit
position
COVID-19
Lead sponsor: Gaziosmanpasa Research and Education Hospital
Sponsor class: OTHER_GOV
First posted: 2020-06-16
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: patients will be divided into two groups, those with and without ultrasound.
Primary purpose: OTHER

Brief summary: In COVID-19 patients hospitalized in the intensive care unit due to respiratory failure, lung ultrasonography will be tried to be given an appropriate position that will effectively use lung capacity and its effect on oxygenation will be investigated.

Detailed description: In this study, the COVID-19 patients hospitalized in the intensive care unit due to respiratory failure will be evaluated. Participants will be divided into two groups as patients undergoing lung ultrasonography (Group Ultrasonography ) and those without lung ultrasonography (Group Control).

While performing lung ultrasonography, each hemithorax will be evaluated using anterior axillary line and posterior axillary line into anterior, lateral and posterior region, and each region will be divided into 6 quadrants, upper and lower. Each hemithorax will be scanned by the investigators, scored in 6 regions using a convex ultrasonography probe with the Lung Ultrasound Score (LUS score).

Participants in both groups will be evaluated by comparing arterial blood gas analyzes before examination (with/without ultrasonography), at the 2nd and 12th hours. Is there any change in arterial blood gas values such as PO2 and PCO2 at 0, 2 and 12 hours so that oxygenation and ventilation between Group Ultrasonograpy and Group Control will be evaluated?

Eligibility criteria: Inclusion Criteria:

* Patients have been diagnosed with COVID 19
* Patients in the intensive care unit over the age of 18

Exclusion Criteria:

* Patients not diagnosed with COVID 19
* Patients with cardiac problems
* Patients with renal problems

Primary outcomes:
measure: Change in PO2 values
timeFrame: 12 hours
Secondary outcomes:
measure: Change in PCO2 values
timeFrame: 12 hours
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Gazoosmanpasa Education and Research Hospital
Study officials:
References:
Clinical trial NCT04439851: Impact of Sleeve Gastrectomy on Monocyte-to-High-Density Lipoprotein Cholesterol Ratio
Official title: The Relationship Between Monocyte-to-High-Density Lipoprotein Cholesterol Ratio, Metabolic Parameters and Excess Weight Loss in Patients Undergoing Laparoscopic Sleeve Gastrectomy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Laparoscopic Sleeve Gastrectomy
Cardiovascular Risk Factor
Obesity
Lead sponsor: Umraniye Education and Research Hospital
Sponsor class: OTHER_GOV
First posted: 2020-06-19
Enrollment: 125
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Obese patients (BMI ≥40 or \>35+ and accompanying DM, HT and hyperlipidemia)

Brief summary: The present study hypothesized that significant weight loss is associated with a reduction in the inflammatory markers, leading to diminished cardiovascular risks in patients undergoing laparoscopic sleeve gastrectomy (LGS).

We found a decrease in MHR at postoperative 6 months from baseline in patients undergoing LSG. The decrease in MHR was more remarkable with increasing percentage of EWL, but no relationship between the %EWL and MHR.

Detailed description: The present study aims to evaluate the relationship between MHR, metabolic parameters and the percentage of excess weight loss (%EWL) in participants undergoing laparoscopic sleeve gastrectomy (LSG).

This prospective cohort study will evaluate obese participants undergoing LSG. Demographic data of the participants and blood glucose level, monocyte count and lipid parameters baseline and at 6 months after surgery will record. The MHR baseline and at 6 months after surgery and the %EWL at 6 months after surgery will calculate. The participants will be divide into two groups as participants with %EWL of \<50 and patients with a %EWL of ≥50. The parameters will compare between the two groups.

Eligibility criteria: Inclusion Criteria:

Obese patients (BMI ≥40 or \>35+ and accompanying DM, HT and hyperlipidemia) Underwent laparoscopic sleeve gastrectomy.

Exclusion Criteria:

Receiving antihyperlipidemic therapy, Important complications that continue within 6 months after surgery (anastomotic leaks, pulmonary embolism, deep vein thrombosis, soft tissue infection) Did not attend 6-month control visit were excluded from the study.

Primary outcomes:
measure: Monocyte-to-High-Density Lipoprotein Cholesterol Ratio changes
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01711151: Interstitial Lung Disease Questionnaire
Official title: Questionnaire Study for Patients With Interstitial Lung Disease
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Interstitial Lung Disease
Keywords: ILD
Lead sponsor: University of East Anglia
Sponsor class: OTHER
First posted: 2012-10-22
Enrollment: 304
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Secondary Care

Brief summary: 1. To evaluate the health status of patients with Interstitial Lung Disease (ILD), and how this varies between subgroups of ILD.
2. To investigate the prevalence of symptoms, anxiety, depression, and sleep-disordered breathing within ILD patient population.
3. To assess the economic impact of ILD.
4. To understand how self-aware ILD patients are regarding their treatment/management.
5. To compare the demographic details, including smoking status and occupational history, of patients with interstitial lung disease

Detailed description: Primary endpoint

• Health status in the target populations, as determined by the K-BILD questionnaire.

Secondary endpoints -

* Severity of dyspnoea suffered by patients
* Prevalence of anxiety and depression
* Prevalence of sleep-disordered breathing symptoms
* Degree of self-awareness displayed by patients
* The costs associated with ILD from a patient and healthcare perspective.
* Demographic details

Eligibility criteria: Inclusion Criteria:

* Male or female
* Age greater than 18 years of age
* Any smoking status
* Diagnosis of Interstitial Lung Disease as defined below
* Full pulmonary lung function tests and routine immunological tests undertaken within 6 months of entry into study

Exclusion Criteria:

• Unable to give consent to take part

Primary outcomes:
measure: Difference in the Mean K-BILD score between the 4 groups
timeFrame: Baseline
Secondary outcomes:
measure: Severity of dyspnoea suffered by patients
timeFrame: Baseline
measure: Prevalence of anxiety and depression
timeFrame: Baseline
measure: Prevalence of sleep-disordered breathing symptoms
timeFrame: Baseline
measure: Degree of self-awareness displayed by patients
timeFrame: Baseline
measure: The costs associated with ILD from a patient and healthcare perspective
timeFrame: Baseline
measure: Demographic details
timeFrame: Baseline
Other outcomes:
Locations:
city: Norwich
country: United Kingdom
facility: Norfolk and Norwich Univeristy Hospital NHS foundation Trust
state: Norfolk
Study officials:
affiliation: University of East Anglia
name: Andrew M Wilson
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06071351: Motivational Interviewing Effect on Reducing Cardiovascular Disease Risk Factors
Official title: Motivational Interviewing Based Training Program in Adults Effect on Reducing Cardiovascular Disease Risk Factors: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Cardiovascular Diseases
Motivation
Nurse's Role
Risk Reduction
Keywords: cardiovascular disease
motivational interviewing
risk reduction
nurse's role
Lead sponsor: Muş Alparslan University
Sponsor class: OTHER
First posted: 2023-10-06
Enrollment: 40
Sex: ALL
Minimum age (years): 40
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Parallel Assignment
Primary purpose: PREVENTION

Brief summary: Aim: The aim of this study is to examine the effect of motivational interviewing-based training program on reducing cardiovascular disease risk factors in adults.

Methods: In the first stage, individuals' CVD risk levels were determined. In the second stage, a 6-session motivational interview-based training program was applied to the intervention group with a medium CVD risk level (HearthSCORE score between 2 and 5 points). Brochures were distributed to the control group.

Detailed description: The aim of this study is to determine the CVD risks of adult individuals between the ages of 40-70 and to evaluate the effect of a motivational interview-based training program on reducing modifiable risk factors in individuals with moderate CVD risk.

Hypothesis; A 6-session motivational interview-based training program aimed at reducing CVD risk factors reduces the risk level in the intervention group more than the control group.

This study will be carried out in 2 stages. In the first phase, risk prevalence screening will be carried out to determine the CVD risks of individuals between October and November 2023. In the 2nd phase, a randomized controlled study will be conducted to evaluate the intervention program for individuals at medium risk level (HeartScore® between 2 and 5).

Eligibility criteria: Inclusion Criteria:

* Being aged between 40 and 70 years,
* Being voluntary to participate in the study,

Exclusion Criteria:

* Having a known and diagnosed CVD
* Not being voluntary to participate in the study.

Primary outcomes:
measure: change is CVD risk level
timeFrame: 24 week
Secondary outcomes:
measure: Change in Physical Activity Level
timeFrame: 24 week
Other outcomes:
Locations:
city: Antalya
country: Turkey
facility: Kepez Devlet Hastanesi
Study officials:
References:
Clinical trial NCT04896151: Assessing the Utility of MMPI-2-RF-EX in Detecting Simulated Underreporting of Current Suicide Risk in Military Veterans
Official title: Assessing the Utility of MMPI-2-RF-EX in Detecting Simulated Underreporting of Current Suicide Risk in Military Veterans
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Suicidal Ideation
Suicidal
Lead sponsor: Ohio State University
Sponsor class: OTHER
Collaborators: name: University of Minnesota
name: Rutgers University
First posted: 2021-05-21
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The aim of the current project are is examine the incremental predictive utility of the MMPI-2-RF-EX validity scales in detecting simulated underreporting of suicide risk on the MMPI-2-RF-EX and other self-report measures of suicide risk in 150 military Veterans experiencing past-month death or suicidal ideation.


Eligibility criteria: Inclusion Criteria:

* 18 years of age or older
* US military veteran
* death or suicidal ideation/suicide attempt within the past month

Exclusion Criteria:

* non-Veteran status
* acute intoxication or active psychosis precluding provision of informed consent
* an inability to communicate and comprehend English
* residence outside the United States
* lack of past-month death/suicide ideation or attempt
* younger than 18 years of age

Primary outcomes:
measure: MMPI-2-RF-EX Suicidal/Death Ideation scale
timeFrame: Baseline
measure: Beck Scale for Suicide Ideation (BSS)
timeFrame: Baseline
Secondary outcomes:
measure: Suicide Cognitions Scale (SCS)
timeFrame: Baseline
Other outcomes:
measure: Short Grit Scale
timeFrame: Baseline
measure: MMPI Posttest Inquiry (PTI)
timeFrame: Baseline
measure: PTSD Checklist for DSM-5 (PCL-5) PTSD Checklist for DSM-5
timeFrame: Baseline
Locations:
city: Columbus
country: United States
facility: The Ohio State University
state: Ohio
Study officials:
affiliation: Ohio State University
name: Lauren Khazem, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04390451: Initial Testing of Whole Health STEPS
Official title: Initial Testing of Whole Health STEPS (Structured Tiered Engagement With Peer Support)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Mental Health
Keywords: Primary Health Care
Mental Health
Lead sponsor: VA Office of Research and Development
Sponsor class: FED
First posted: 2020-05-15
Enrollment: 82
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The study compares Whole Health STEPS to a waitlist control.
Primary purpose: SUPPORTIVE_CARE

Brief summary: This clinical trial is evaluating Whole Health STEPS (Structured Tiered Engagement with Peer Support), a package of services designed to improve functional outcomes for primary care Veterans with mental health concerns who are not actively engaged in mental health services. Whole Health STEPS uses a Peer Support Specialist, or Peer, to provide support for Veterans to make progress on wellness goals using the Whole Health model. The level of support provided will be determined based on Veterans' progress and will be stepped-up until Veterans receive the level of support they need. Whole Health STEPS offers a non-mental health referral option for primary care Veterans with mental health concerns, provides a structured package of existing Whole Health services, and provides a structured service for peers in primary care settings.


Eligibility criteria: Inclusion Criteria:

* Veteran status
* Enrolled in primary care at a participating site
* Have at least mild functional impairment
* Screen positive on at least one primary care mental health screener

Exclusion Criteria:

* Actively engaged with an equivalent or higher level of care
* Preference for direct referral to mental health care
* Recent changes to psychotropic medications
* Severe impairment preventing engagement in the intervention or warranting a direct referral to a licensed independent provider
* Inability to independently communicate in verbal and written English
* Inability to complete the research tasks or intervention

Primary outcomes:
measure: Inventory of Psychosocial Functioning (IPF)
timeFrame: 4 months
Secondary outcomes:
Other outcomes:
Locations:
city: Syracuse
country: United States
facility: Syracuse VA Medical Center, Syracuse, NY
state: New York
Study officials:
affiliation: Syracuse VA Medical Center, Syracuse, NY
name: Emily M. Johnson, PhD
role: PRINCIPAL_INVESTIGATOR
References: